Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio

Positioned As ‘Off-The-Shelf’ Rival To CAR-Ts

Executive Summary

Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.

You may also be interested in...



Genmab Confident It Has Edge Over Roche In Bispecific Battle

Genmab may only recently have launched its first commercial operations with Tivdak, but is stepping up to co-market epcoritamab with AbbVie against the might of Roche in the new CD20xCD3 field.

ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics

Roche looks set to gain first and second place in the race to bring CD3xCD20s to market – but Genmab and AbbVie have a strong challenger.

Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space

The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel